Phase I--study with aprosulate, a new synthetic anticoagulant.

Abstract

This paper describes the first human study with aprosulate, a new chemically synthesized anticoagulant with a defined molecular structure and a molecular weight of 2388. Twelve healthy male volunteers received subcutaneous injections of placebo on the first day followed by ascending doses of aprosulate in the range of 0.25 mg/kg to 2.0 mg/kg body weight on alternate days. Anticoagulant, pharmacokinetic and safety parameters were assessed for 48 hours after each injection. The activated partial thromboplastin time and the Heptest showed a dose-dependent increase for up to ten hours after each application. A trend towards prolongation of the bleeding time was indicated with higher doses. In general, the tolerance was good. Plasma transaminase concentrations were raised in some volunteers but returned spontaneously to normal during or after the study.

• Authors: U E Papoulias, P J Wyld, S Haas, A Stemberger, W Jeske, D Hoppensteadt, A Kämmereit
• Journal: Thrombosis research (Thromb Res) Vol. 72 Issue 2 Pg. 99-108 (Oct 15 1993) ISSN: 0049-3848 [Print] United States
• PMID: 8303655 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article)

Chemical References

• Anticoagulants
• Disaccharides
• aprosulate

Topics

• Adolescent
• Adult
• Anticoagulants (adverse effects, pharmacokinetics, therapeutic use)
• Disaccharides (adverse effects, pharmacokinetics, therapeutic use)
• Dose-Response Relationship, Drug
• Humans
• Male
• Molecular Weight
• Single-Blind Method